FDA Grants Formal Approval to Rechembi: A Breakthrough Drug for Alzheimer’s Disease
Eisai and Biogen Receive FDA Approval for Alzheimer’s Disease Drug Rechembi In a major breakthrough, the United States Food and Drug Administration (FDA) has officially approved Rechembi (recanemab), a drug developed jointly by Eisai of Japan and Biogen of the United States for the treatment of Alzheimer’s disease. This landmark decision has garnered significant attention […]
Alzheimer’s treatment ‘Rechembi’ is on the verge of full approval… Is it possible to fundamentally cure dementia?
Rechembi, jointly developed with Biogen and Eisai, received a recommendation for official approval from the US FDA In phase 3 clinical trials, mild progression and cognitive decline were delayed by 27% compared to placebo It is expected to be the latest treatment that targets and affects the underlying mechanism of Alzheimer’s disease Rechembi global sales […]
